UnknownNot Applicable

Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)

10 participantsStarted 2019-03-01

Plain-language summary

This is a prospective study which aims to explore the effect of Trimetazidine on the improvement of coronary microvascular dysfunction in patients with INOCA (ischemia and no obstructive coronary artery disease). Enrolled patients will be assessed SAQ(Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR(coronary flow reserve) .CFR inspection with D-SPECT and pressure guide wire.Patients will receive six months Trimetazidine(35mg tid) after enrollment. And their SAQ (Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR will be followed up.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age≥18 years * Typical angina symptoms * Coronary angiography or coronary computed tomography examination showed no significant epicardial coronary artery stenosis (\<20%) * Never used trimetazidine * The CFR measured by the pressure guide wire is less than 2.0 * agree to participant the study and sign informed written consent * available for six months follow up Exclusion Criteria: * Severe liver and kidney disease * Contraindications of Trimetazidine * Use of CYP3A inhibitors, such as diltiazem, verapamil, and other drugs that may affect CFR measurements * QT interval extension * Atrial fibrillation or left bundle branch block * Left ventricular systolic dysfunction (EF \<55%) * Coronary artery fistula * Myocardial bridge * Non-cardiogenic chest pain and other heart diseases * Severe heart valve disease * Diabetes * Recent ACS( Acute coronary syndrome) * Pregnancy * Failed to complete inspection

What they're measuring

Coronary flow reserve (CFR) improves

Timeframe: six months

Trial details

NCT IDNCT03504202

SponsorShanghai 10th People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-04-01